MIRM Latest Press Releases

-- November 12, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- November 10, 2026 --

Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD Business Wire 7:30 AM

-- November 3, 2026 --

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Business Wire 4:01 PM

-- November 2, 2026 --

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting 2026 Business Wire 8:02 AM

-- October 27, 2026 --

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026 Business Wire 4:01 PM

-- October 26, 2026 --

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva Business Wire 6:50 PM

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva Business Wire 8:00 AM

-- October 21, 2026 --

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 4:01 PM

-- October 15, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- October 12, 2026 --

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Business Wire 8:00 AM

-- October 11, 2026 --

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Business Wire 5:00 PM

-- September 28, 2026 --

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus Business Wire 8:00 AM

-- September 27, 2026 --

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 Business Wire 5:00 PM

-- September 25, 2026 --

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva Business Wire 7:00 PM

-- September 14, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- September 8, 2026 --

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer Business Wire 8:30 AM

-- August 11, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- August 5, 2026 --

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 4:01 PM

-- July 29, 2026 --

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Business Wire 4:01 PM

-- July 13, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

Market Data Delayed 15 Minutes